Status:
UNKNOWN
Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery
Lead Sponsor:
CHU de Quebec-Universite Laval
Conditions:
Urinary Retention
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
Post-operative urinary retention (POUR) is a frequent complication reported as ranging from 10 to 55% in the literature. In a recent retrospective study from Laliberte et al in Quebec City, we observe...
Detailed Description
We are conducting a feasibility study (Vanguard phase) with three Canadian centers : 1. CHU de Quebec - Laval University, Quebec City, Quebec, Canada 2. St-Paul's Hospital, Vancouver, British-Columbi...
Eligibility Criteria
Inclusion
- Male patients of 18 years and older that are scheduled for a TEM resection during the study period.
Exclusion
- Patient already taking an alpha1-adrenergic blocking agent Flomax® (Tamsulosin), Cardura® (Doxazosin), Hytrin® (Terazosine) Rapaflo® (Silodosin), Xatral® (Alfuzosin), Minipress® (Prazosin)
- Patient having an indwelling bladder catheter
- Allergy or hypersensibility to any alpha1-adrenergic blocking agent
- Patient taking one of the following:
- Anti-retroviral therapy, Antifungal drug, Clarithromycin, Erythromycin, Paroxetine, Terbinafine, Cimetidine, Warfarin, Sildenafil, Tadalafil, Vardenafil (these drugs have possible interactions with the study drug)
Key Trial Info
Start Date :
October 6 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT03314025
Start Date
October 6 2017
End Date
October 1 2022
Last Update
May 19 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Paul's Hospital
Vancouver, British Columbia, Canada, V6Z 1Y6
2
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1Y 4E9
3
CHU de Quebec - Universite Laval
Québec, Quebec, Canada, G1L 3L5